Determinants of early discontinuation of etonogestrel sub-dermal implant among reproductive-age women in Legambo district, Northeast Ethiopia: An unmatched case–control study

Yesuf Yimer, Niguss Cherie and Yitayish Damtie

Abstract

Objective: Etonogestrel sub-dermal implant discontinuation is very common in the study area. But evidence on the determinants was limited. So, this study aimed to identify determinants of early discontinuation of etonogestrel sub-dermal implant among reproductive-age women in Legambo district, Northeast Ethiopia.

Methods: An institution-based unmatched case–control study was conducted on 252 reproductive-age women (84 cases and 168 controls) from 1 February up to 30 April 2020. Systematic random sampling was used to select women, and the data were collected by face-to-face interview using a structured, pretested, and interviewer-administered questionnaire. The collected data were entered into Epi Data version 3.1 and analyzed by SPSS version 23. A binary logistic regression model was used to identify determinants of early discontinuation of etonogestrel sub-dermal implant. Statistical significance was declared at a p value of less than 0.05, and adjusted odds ratio with a 95% confidence interval was used to identify determinants of early discontinuation of etonogestrel sub-dermal implant in the final model.

Result: In this study, not receiving pre-insertion counseling (adjusted odds ratio = 3.19, 95% confidence interval: (1.61, 6.30)), having a history of abortion (adjusted odds ratio = 2.89, 95% confidence interval: (1.50, 5.54)), contraceptive side effects (adjusted odds ratio = 2.45, 95% confidence interval: (1.99, 3.91)), and not receiving an appointment for a follow-up visit at the time of insertion (adjusted odds ratio = 3.45, 95% confidence interval: (1.89, 5.99)) were determinants of early discontinuation of etonogestrel sub-dermal implant.

Conclusion: Not receiving pre-insertion counseling, having a history of abortion, contraceptive side effects, and not receiving an appointment for a follow-up visit at the time of insertion were predictors of early discontinuation of etonogestrel sub-dermal implant. Thus, healthcare professionals should give an appointment for a follow-up visit at the time of insertion and provide detailed counseling for all women, not only for those who had had an abortion and contraceptive side effects.

Keywords

Etonogestrel sub-dermal implant, discontinuation, removal, family planning, Ethiopia

Date received: 30 September 2021; accepted: 28 February 2022
compliance and is associated with prompt fertility return after removal.5

Globally, more than 4.5 million women have used etonogestrel sub-dermal implant.6 However, despite its good tolerance, reversibility, and effectiveness, 18%–63% of women in developing countries who are still in need discontinued contraception.7,8 Early etonogestrel sub-dermal implant discontinuation is defined as the removal of the implant less than 3 years of use after the insertion.9 The discontinuation rate of etonogestrel sub-dermal implant varies across countries. A study conducted in the United States indicated that 25.2% of women discontinue the implant within 10.4 months.10 Studies conducted in the United Kingdom and Malaysia, the Netherlands, and Jordan also indicated that 23%, 28%, and 45% of women discontinue etonogestrel sub-dermal implant within 1 year of initiating the method, respectively.11–13

The discontinuation rate is significantly higher in Africa. Studies conducted in Egypt, South Africa, Nigeria, Liberia, and Yemen showed that 36, 43%, 19%, 23%, and 69% of women discontinue etonogestrel sub-dermal implant before the completion of 3 years, respectively.11,14–16

Etonogestrel sub-dermal implant is provided free of charge for women in Ethiopia. In addition, the Ethiopian Federal Ministry of Health (FMOH) developed a program to scale up this contraceptive method at the community level to meet the huge unmet need in family planning since the beginning of 2010.17 Despite this effort, the early discontinuation rate within 12 months increased from 5% in 2011 to 11% in 2016.18,19 In Legambo district, the annual report showed that 11.3 % of reproductive-age women use etonogestrel sub-dermal implant, and among these, 31% of them discontinued before 3 years of use for unknown reasons.20

Contraceptive discontinuation has a substantial contribution to the occurrence of negative reproductive health outcomes. It places a woman at risk of unintended pregnancy, induced abortions, and ultimately can lead to maternal and child mortality.21–26 It also increases the total fertility rate, reduces educational attainment, and may result in negative social and economic consequences.11,27–30

Socioeconomic factors such as age, marital status, educational status, parity, dissatisfaction with services,31–35 contraceptive side effects,36–39 desire to become pregnant, spouse disapproval, and switching to another method37,38,40,41 were the common factors affecting early discontinuation of etonogestrel sub-dermal implant.

Improving the utilization rate of modern contraceptive methods, in general, and etonogestrel sub-dermal implant, in particular, is of paramount importance for tackling different maternal and child health problems to achieve Sustainable Developmental Goals (SDGs) and Growth and Transformation Plan Two (GTPII).42,43 Early discontinuation of etonogestrel sub-dermal implant in Legambo district was higher. But evidence on the determinants was limited. So, this study aimed to identify determinants of early discontinuation of etonogestrel sub-dermal implant among women in Legambo district, Northeast Ethiopia, 2020.

Methods and materials

Study area, period, and design

An institution-based unmatched case–control study was conducted from 25 February to 10 April 2020 in public health facilities of Legambo district. The district is located 623 km away from Bair Dar, the city of Amhara regional state, and 501 km away from Addis Ababa, the capital city of Ethiopia. The district has 40 administrative kebeles with a total population of 203,676. Of these, 29,987 were women of reproductive age. It has one primary hospital and nine health centers.

Population

The source population for the cases and controls: All reproductive-age women who were still using etonogestrel sub-dermal implant at the time of the study.

The study population for the cases: All reproductive-age women who request early removal of etonogestrel sub-dermal implant before 3 years following insertion during the study period.

The study population for the controls: All reproductive-age women who request the removal of etonogestrel sub-dermal implant at three completed years following insertion during the study period.

Inclusion and exclusion criteria

All women who requested early removal of etonogestrel sub-dermal implant before 3 years following insertion in the health facilities during the study period were included as cases and all women who requested the removal of etonogestrel sub-dermal implant at 3 years following insertion in the health facilities during the study period were included as controls. Women who had severe illnesses and were not able to provide the required information were excluded.

Sample size determination and sampling procedure

The sample size was calculated using Epi Info version 7.1 by taking the assumption of early discontinuation of etonogestrel sub-dermal implant among women who did not experience contraceptive side effects as 56.5% based on the study done in Mekelle city,44 the ratio of exposed to unexposed as 1:2, Adjusted Odds Ratio (AOR) as 2.66, power of 80%, and confidence level of 95%. Thus, the required sample size after adding a 10% non-response rate becomes 252 (84 cases and 168 controls).
Among the 10 health facilities in the Legambo district, 5 of them were selected by simple random sampling method. Then after proportional allocation to the selected health facilities, women were selected using the systematic random sampling technique until reaching the final sample size. Women were selected in every second case, followed by two succeeding controls from their sequence of family planning visits in each health facility during the study period. The random start, which was selected by the lottery method, was the second woman who requested the removal of the etonogestrel sub-dermal implant before the expiry date.

Data collection tools, procedures, and measurements

Data were collected by face-to-face interview using a structured and pretested questionnaire taken from previous similar works of literature. The questionnaire was composed of contraceptive-related characteristics, obstetric characteristics, contraceptive-related characteristics, and client-related characteristics. One Bachelor of Science (BSc) midwife supervisor and two diploma midwifery and three diploma nurses were assigned for the data collection. Data were collected in the ratio of one case for every two succeeding controls in each health facility until reaching the final sample size.

Early etonogestrel sub-dermal implant discontinuation: removal of etonogestrel sub-dermal implant by the health-care provider before 3 years following insertion.

Knowledge: Women’s level of knowledge toward etonogestrel sub-dermal implant was assessed using seven “yes” or “no” answer questions, that is, Does etonogestrel sub-dermal implant delay pregnancy upon discontinuation? Can it provide effective protection from pregnancy for up to 3 years? Does it require a minor surgical procedure for removal? Does it have any interference with sexual intercourse or desire? Can it be discontinued at any time? Does it require little attention after insertion? Is it inserted in the left upper arm? It was measured as “having good knowledge” if respondents scored at or above median value and “having poor knowledge” if respondents scored below the median value.

Attitude: Attitude toward etonogestrel sub-dermal implant was assessed using six questions, that is, etonogestrel sub-dermal implant insertion and removal are highly painful, it has severe side effects, using etonogestrel implant restricts normal activities, etonogestrel sub-dermal implant causes severe changes in menstrual bleeding pattern, it is difficult to remove etonogestrel sub-dermal implant, and etonogestrel sub-dermal implant requires frequent follow-up. Each question has five response options taking a score between 1 and 5 (1 = strongly disagree, 2 = disagree, 3 = neutral, 4 = agree, and 5 = strongly agree). Since the data were not normally distributed, the median score was used as a cut-off point to categorize women’s attitudes toward etonogestrel sub-dermal implant. As a result, those women who scored at or above the median were considered to have a positive attitude and those women who scored below the median were considered to have a negative attitude toward Implanon.

Data quality control

To ensure consistency, the questionnaire developed in English was translated into Amharic language and again translated back to English by language experts. The supervisor and data collectors were trained for 1 day on the objective of the study, the contents of the questionnaire, and the data collection procedure. The questionnaire was pretested on 5% (13) of women (4 cases and 9 controls) at Genete Health Center, one of the health centers in the district, and based on the feedback obtained from the pretest, the necessary modification was done accordingly. During the study period, the collected data were checked continuously on a daily basis for completeness by the principal investigator and supervisor in the respective health facilities.

Data processing and analysis

The collected data were cleaned, coded, and entered into Epi Data version 3.1 and exported to Statistical Package for Social Science (SPSS) version 23 statistical software for statistical analysis. Descriptive statistics, such as frequencies, proportion, and summary measures (median with Inter-Quartile Range (IQR)), were computed. The association between independent variables and early discontinuation of etonogestrel sub-dermal implant was tested using a binary logistic regression model, and all independent variables having a p-value of less than or equal to 0.2 were included in the multivariable logistic regression model. Multicollinearity was checked using standard error, and the Hosmer and Lemeshow test was used to check model fitness. Statistical significance was declared using Odds Ratios (ORs) with 95% CIs and p-value; p-value less than 0.05 and AOR with 95% CI non-inclusive of 1 were considered as statistically significant and used to determine predictors of early etonogestrel sub-dermal implant discontinuation in the final model. Besides, survival analysis was carried out to see the effect of some important variables on early discontinuation of etonogestrel sub-dermal implant.

Results

Socio-demographic characteristics

A total of 252 respondents (84 cases and 168 controls) have participated in the study with a response rate of 100%. The median age of the study participants was 27 years with an IQR of 8 years. The median (IQR) duration of etonogestrel sub-dermal implant usage among cases was 18 (10) months, with the duration ranging from 5 to 33 months. Most study participants in this study were married (Table 1).
The majority of study participants were multiparous and had less than or equal to three children. Many of them have been counseled about the side effects of etonogestrel sub-dermal implant, and most of them have good knowledge and a positive attitude toward etonogestrel sub-dermal implant (Table 2).

Determinants of early discontinuation of etonogestrel sub-dermal implant

Both bivariable and multivariable logistic regression analyses were done. As a result, history of abortion, contraceptive side effects, not receiving pre-insertion counseling, and not receiving an appointment for a follow-up visit at the time of insertion were factors significantly associated with early etonogestrel sub-dermal implant discontinuation.

Those women who had a history of abortion were almost 3 times more likely to discontinue etonogestrel sub-dermal implant early than those women who had no history of abortion (AOR = 2.89; 95% CI: (1.50, 5.54)). The study also revealed that the odds of discontinuing etonogestrel sub-dermal implant early were 2.5 times higher among women who experienced contraceptive side effects as compared to their counterparts (AOR = 2.45, 95% CI: (1.99, 3.91)). Women who have not received pre-insertion counseling about etonogestrel sub-dermal implant were 3.2 times more likely to discontinue etonogestrel sub-dermal implant early than those women who have been counseled before insertion (AOR = 3.19; 95% CI: (1.61, 6.30)). Similarly, those women who have not received an appointment for a follow-up visit at the time of insertion were 3.45 times more likely to discontinue etonogestrel sub-dermal implant early than those who received a follow-up appointment (AOR = 3.45; 95% CI: (1.89, 5.99)) (Table 3).
compared to their counterparts (Adjusted Hazard Ratio (AHR) = 1.79; 95% CI: (1.17, 2.96)). Similarly, women who have not received an appointment for a follow-up visit at the time of insertion were 1.69 times more likely to discontinue the method early than their counterparts (AHR = 1.69; 95% CI: (1.26, 3.71)) (Table 4).

### Discussion

To effectively confront the unreserved contraceptive discontinuation among women in Ethiopia, in general, and Legambo district, in particular, determinant factors influencing early discontinuation of etonogestrel sub-dermal implant need to be investigated. In this study, having a history of abortion, contraceptive side effects, not receiving pre-insertion counseling, and not receiving an appointment for a follow-up visit at the time of insertion were 1.69 times more likely to discontinue the method early than their counterparts (AHR = 1.69; 95% CI: (1.26, 3.71)) (Table 4).

This finding is consistent with previous studies conducted in Diguna Fango district and Australia. It is also supported by a survival analysis result. The possible explanation would be that women who had a history of abortion might discontinue etonogestrel sub-dermal implant early due to fear of childlessness as a result of the double burden of abortion and contraception.

Women who experienced etonogestrel sub-dermal implant side effects were at high risk of early etonogestrel sub-dermal implant discontinuation. The finding was in agreement with other studies conducted in Ethiopia, Uganda, Egypt, Kinshasa, Turkey, Jos Nigeria, and Jordan. The possible reason might be inadequate pre-insertion counseling about the possible side effects. Studies indicated that the early discontinuation rate was higher among women who had not been adequately counseled about the side effects of the Implanon. The other reason might be women’s little intolerance to the newly occurring minor side effects of the method. Although the etonogestrel sub-dermal implant has no serious effects on the health of the women,

### Table 2: Women obstetric, contraceptive, and client-related characteristics living in Legambo district, Northeast Ethiopia, 2020.

| Variables                              | Categories       | Cases(84), n (%) | Controls (168), n (%) | χ², df | p-value |
|----------------------------------------|------------------|------------------|-----------------------|--------|---------|
| Parity                                 | Nulliparous      | 31 (37)          | 59 (35)               | 0.078, 1 | 0.780   |
|                                        | Multiparous      | 53 (63)          | 109 (65)              |        |         |
| Number of live children                | ≤3               | 44 (83)          | 77 (71)               | 2.397, 1 | 0.230   |
|                                        | >3               | 9 (17)           | 32 (29)               |        |         |
| History of abortion                    | Yes              | 37 (44)          | 45 (27)               | 7.602, 1 | 0.006   |
| Having a desire for more children      | Yes              | 49 (58)          | 78 (46)               | 3.175, 1 | 0.075   |
| Ever used an etonogestrel implant before| Yes              | 32 (38)          | 86 (51.2)             | 4.968, 1 | 0.026   |
| Wanted to shift the method             | Yes              | 47 (56)          | 56 (33)               | 1.855, 1 | 0.571   |
| Contraceptive side effect              | Yes              | 45 (53.8)        | 65 (38.7)             | 5.042, 1 | 0.025   |
| Received pre-insertion counseling      | Yes              | 51 (61)          | 122 (73)              | 8.488, 1 | 0.004   |
| Given follow-up appointment at the time of insertion | Yes | 27 (32) | 94 (56) | 12.718, 1 | <0.001 |
| Place of insertion                     | Health unit      | 32 (38)          | 53 (36)               | 1.116, 2 | 0.572   |
|                                        | Health center    | 37 (44)          | 80 (48)               |        |         |
|                                        | Hospital         | 15 (18)          | 35 (26)               |        |         |
| Decision on etonogestrel sub-dermal implant | Client       | 42 (50)          | 87 (52)               | 7.185, 3 | 0.066   |
|                                        | Husband          | 4 (5)            | 23 (13)               |        |         |
|                                        | With husband jointly | 13 (15) | 40 (24) |        |         |
| Professional who inserted etonogestrel sub-dermal implant | HEW | 25 (30) | 16 (11) | 1.074, 1 | 0.300   |
|                                        | Health professionals | 52 (62) | 116 (68) |        |         |
| Knowledge about etonogestrel sub-dermal implant | Good | 47 (56) | 106 (63) | 1.198, 1 | 0.274   |
| Attitude toward etonogestrel sub-dermal implant | Poor | 37 (44) | 62 (37) | 0.066, 1 | 0.797   |
|                                        | Positive         | 73 (86.9)        | 144 (85.7)            |        |         |
|                                        | Negative         | 11 (13.1)        | 24 (14.3)             |        |         |

HEW: health extension workers.
they might be more worried about their sexual experience as a result of unfavorable bleeding patterns and would want the etonogestrel sub-dermal implant to be removed early in order not to interfere with their sexual relationship.

Not receiving an appointment for a follow-up visit at the time of insertion also had a positive association with early etonogestrel sub-dermal implant discontinuation similar to studies conducted in Diguna Fango district and Debre Tabor town. The finding is also supported by the survival analysis result. Women who have not received pre-insertion counseling may not accept and tolerate minor side effects, and possibly they may seek early removal of the method. On the other hand, the information provided during counseling can clear their concerns or misconceptions related to the method causing early discontinuation.

### Table 3. Factors associated with early etonogestrel sub-dermal implant discontinuation among women in Legambo district, Northeast Ethiopia, 2020.

| Variables                              | Early etonogestrel sub-dermal implant discontinuation | COR (95% CI) | AOR (95% CI) |
|----------------------------------------|------------------------------------------------------|--------------|--------------|
|                                        | Early etonogestrel sub-dermal implant discontinuation | COR (95% CI) | AOR (95% CI) |
|                                        | Yes | No | 1 | 1 |
| Residence                              |     |     |     |     |
| Urban                                  | 37  | 99 | 1 | 1 |
| Rural                                  | 47  | 69 | 1.82 (0.75, 3.09) | 1.32 (0.61, 6.30) |
| Maternal occupation                    |     |     |     |     |
| Housewife                              | 17  | 55 | 1 | 1 |
| Merchant                               | 15  | 38 | 1.28 (0.5, 2.87) | 0.91 (0.36, 2.32) |
| Employed                               | 23  | 30 | 2.48 (1.15, 5.35)* | 1.98 (0.82, 4.84) |
| Student                                | 7   | 17 | 1.33 (0.47, 3.75) | 1.09 (0.32, 3.70) |
| Farmer                                 | 22  | 28 | 2.54 (1.17, 5.54)* | 3.2 (0.27, 8.29) |
| Wanted to shift the method             |     |     |     |     |
| Yes                                    | 47  | 56 | 2.54 (0.49, 4.35) | 2.66 (0.22, 4.18) |
| No                                     | 37  | 112| 1 | 1 |
| Having a history of abortion           |     |     |     |     |
| Yes                                    | 37  | 45 | 2.15 (1.24, 3.73)* | 2.89 (1.50, 5.54)* |
| No                                     | 47  | 123| 1 | 1 |
| Having a desire for more children      |     |     |     |     |
| Yes                                    | 49  | 78 | 1.61 (0.43, 3.67) | 1.87 (0.72, 4.56) |
| No                                     | 35  | 90 | 1 | 1 |
| Contraceptive side effect              |     |     |     |     |
| Yes                                    | 45  | 65 | 1.83 (1.61, 5.64)* | 2.45 (1.99, 3.91)** |
| No                                     | 39  | 103| 1 | 1 |
| Received pre-insertion counseling      |     |     |     |     |
| Yes                                    | 51  | 122| 1 | 1 |
| No                                     | 33  | 46 | 1.72 (1.23, 5.21)* | 3.19 (1.61, 6.30)* |
| Given follow-up appointment at the time of insertion |     |     |     |     |
| Yes                                    | 27  | 94 | 1 | 1 |
| No                                     | 57  | 74 | 2.68 (1.55, 4.65)** | 3.45 (1.89, 5.99)* |
| Knowledge about etonogestrel sub-dermal implant |     |     |     |     |
| Good                                   | 47  | 106| 1 | 1 |
| Poor                                   | 37  | 62 | 1.34 (1.10, 3.57)* | 1.21 (0.84, 3.11) |
| Attitude toward etonogestrel sub-dermal implant |     |     |     |     |
| Positive                               | 73  | 144| 1 | 1 |
| Negative                               | 11  | 24 | 0.90 (0.61, 2.18) | 1.53 (0.82, 6.37) |

COR: crude odds ratio; CI: confidence interval; AOR: adjusted odds ratio.

*= statistically significant at \( p < 0.05 \) and **= statistically significant at \( p < 0.001 \).

The significance of bold values is to indicate statistically significant predictors/variables.
This study had strength and limitations. As a strength, the study can minimize selection bias as it used hospital controls. As a limitation, this study was a facility-based study, the result of which might not be generalized to the general population. In addition, it is prone to recall bias as the client might experience the difficulty of remembering the date of insertion and removal of etonogestrel sub-dermal implant.

Conclusions

Having a history of abortion, not receiving pre-insertion counseling, not receiving an appointment for a follow-up visit at the time of insertion, and contraceptive side effects were determinants of early etonogestrel sub-dermal implant discontinuation. Healthcare providers should give detailed counseling regarding etonogestrel sub-dermal implant side effects before insertion to increase their retention. They should also give special emphasis to those women who had a history of abortion and should counsel about the benefit of etonogestrel sub-dermal implant for the long-term preparation of women for the next pregnancy. Health professionals should also give appointments for follow-up for close monitoring and management of etonogestrel sub-dermal implant side effects and to increase etonogestrel sub-dermal implant continuation rate. Further research with a qualitative study design would be recommended to explore the unknown factors.

Acknowledgements

We would like to express our deepest gratitude to Wollo University for providing the opportunity and Legambo District Health Office for providing the necessary information to conduct the study. We also would like to thank supervisors, data collectors, and study participants for their cooperation during the data collection process.

Author’s contribution

YY: initiated the research concept, involved in the data collection process, proposal development, data analysis, and interpretation; NC: involved in writing and reviewing the manuscript. YD: involved in writing and reviewing the manuscript; all the authors have read and approved the final manuscript.

Data availability

The datasets used for the current study are available from the corresponding author on reasonable request.

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethical approval

Ethical approval for this study was obtained from the Ethical Review Committee (ERC) of Wollo University College of Medicine and Health Sciences (CMHS-2134/2020). The letter of permission to conduct the study was obtained from each health facility administration.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

After explaining the purpose of the study, written informed consent was obtained from all study participants before the data collection. In the case of minor subjects (aged less than 18 years), written informed consent was obtained from their legally authorized representatives. They were informed that participating in the study is voluntary and the right to withdraw from the study at any time during the interview was assured. Privacy of the client and confidentiality of information they give were secured at all levels and personal identifiers were not used. The information they provide was used for the study purpose.
only. The study also compiles and fulfilled the ethical principles of the Helsinki Declaration in research.

**ORCID iD**

Yitayish Damtie [https://orcid.org/0000-0001-6783-6097](https://orcid.org/0000-0001-6783-6097)

**References**

1. Jacobstein R and Polis CB. Progestin-only contraception: injectables and implants. *Best Pract Res Clin Obstet Gynaecol* 2014; 28(6): 795–806.

2. Bhatia P, Nangia S, Aggarwal S, et al. Implanon: subdermal single-rod contraceptive implant. *J Obstet Gynaecol India* 2011; 61(4): 422–425.

3. Darney P, Patel A, Rosen K, et al. Safety and efficacy of a single-rod etonogestrel implant (Implanon): results from 11 international clinical trials. *Fertil Steril* 2009; 91(5): 1646–1653.

4. Mäkäräinen L, van Beek A, Tuomivaara L, et al. Ovarian function during the use of a single contraceptive implant: Implanon compared with Norplant. *Fertil Steril* 1998; 69(4): 714–721.

5. RamaRao S, Lacuesta M, Costello M, et al. The link between quality of care and contraceptive use. *Int Fam Plan Perspect* 2003; 29(2): 76–83.

6. Asnake M, Henry EG, Tilahun Y, et al. Addressing unmet need for long-acting family planning in Ethiopia: Uptake of single-rod progestogen contraceptive implants (Implanon) and characteristics of users. *Int J Gynaecol Obstet* 2013; 123(Suppl. 1): e29–e32.

7. Bradley SE, Schwandt H and Khan S. Levels, trends, and reasons for contraceptive discontinuation. *DHS Analytical Studies* 20, 2009, https://dhsprogram.com/publications/pdf/AS20/AS20.pdf

8. Harvey C, Seib C and Lucke J. Continuation rates and reasons for removal among Implanon® users accessing two family planning clinics in Queensland, Australia. *Contraception* 2009; 80(6): 527–532.

9. Casey PM, Long ME, Marnach ML, et al. Bleeding related to etonogestrel subdermal implant in a US population. *Contraception* 2011; 83(5): 422–425.

10. United Nations Department of Economic Social Affairs Population Division. World contraceptive patterns, 2013, https://www.un.org/en/development/desa/population/publications/family/contraceptive-wallchart-2013.asp

11. Teunissen AM, Grimm B and Roumen FJ. Continuation rates of the subdermal contraceptive Implanon® and associated influencing factors. *Eur J Contracept Reprod Health Care* 2014; 19(1): 15–21.

12. Islam MM and Marium U. Twin births in Jordan: incidence, trends, risk factors and implications for under-five mortality: evidence from the 2012 Jordan Population and Family Health Survey. *J Biosoc Sci* 2019; 51(6): 857–874.

13. Asnake M and Tilahun Y. Scaling up community-based service delivery of Implanon: the integrated family health program’s experience training health extension workers. Addis Ababa, Ethiopia: Pathfinder International, 2010.

14. Pam VC, Muthir JT, Karshima JA, et al. Factors associated with use and discontinuation of Implanon contraceptive in Jos, Nigeria. *Tropical J Obstetric Gynaecol* 2014; 31(2): 90–99.

15. Balogun OR, Olaomo N, Adeniran AS, et al. Implanon subdermal implant: an emerging method of contraception in Ilorin, Nigeria. *J Med Biomed Sci* 2014; 3(1): 1–5.

16. Staveteig S, Mallick L and Winter R. Uptake and discontinuation of long-acting reversible contraceptives (LARCs) in low-income countries. DHS Analytical Studies No. 54, 2015, https://www.dhsprogram.com/publications/publication-as54-analytical-studies.cfm

17. Federal Democratic Republic of Ethiopia Ministry of Health. National reproductive health strategy: 2006–2015. *Federal Ministry of Health*, 2006, https://www.exemplars.health/-/media/files/egh/resources/underfive-mortality/ethiopia/ethiopia-fmoh_national-reproductive-health-strategy.pdf?la=en

18. Central Statistical Agency [Ethiopia] ICF and International. *Ethiopia Demographic and Health Survey* 2011. Addis Ababa, Ethiopia: Central Statistical Agency, 2011.

19. Central Statistical Agency (CSA) [Ethiopia] ICF. *Ethiopia Demographic and Health Survey* 2016. Addis Ababa, Ethiopia: Central Statistical Agency, 2016.

20. Legambo District Administrative Health Office Annual Health Report, 2018.

21. Henry N, Schluyter M, Lowin J, et al. Cost of unintended pregnancy in Norway: a role for long-acting reversible contraception. *J Fam Plann Reprod Health Care* 2015; 41(2): 109–115.

22. Bradley SE, Polis CB, Bankole A, et al. Global contraceptive failure rates: who is most at risk. *Stud Fam Plann* 2019; 50(1): 3–24.

23. Puri M, Henderson JT, Harper CC, et al. Contraceptive discontinuation and pregnancy postabortion in Nepal: a longitudinal cohort study. *Contraception* 2015; 91(4): 301–307.

24. Sedgh G, Singh S and Hussain R. Intended and unintended pregnancies worldwide in 2012 and recent trends. *Stud Fam Plann* 2014; 45(3): 301–314.

25. Tsui AO, McDonald-Mosley R and Burke AE. Family planning and the burden of unintended pregnancies. *Epidemiol Rev* 2010; 32: 152–174.

26. Curtis S, Evens E and Sambisa W. Contraceptive discontinuation and unintended pregnancy: an imperfect relationship. *Int Perspect Sex Reprod Health* 2011; 37(2): 58–66.

27. Staveteig S, Mallick L, Winter R, et al. Discontinuation of long-acting reversible contraceptives (LARCs) in low-income countries: the role of method access and programmatic quality. In: *Proceedings of the 2016 annual meeting*, 1 April 2016. Vancouver, BC: PAA.

28. World Health Organization. Contraception: discontinuation and switching in developing countries. *Reprod Health Matter* 2012; 2012: 210–212.

29. Madugu NH, Abdul MA, Bawa U, et al. Uptake of hormonal implants contraceptive in Zaria, Northern Nigeria. *Open J Obstetric Gynecol* 2015; 5(5): 268.

30. Ott MA, Sucato GS, Braverman PK, et al. Contraception for adolescents. *Pediatrics* 2014; 134(4): e1257–e1281.

31. Birhane KA, Hagos SE and Fantahun ME. Early discontinuation of Implanon and its associated factors among women who ever used Implanon in Ofla District, Tigray, Northern Ethiopia. *Int J Pharma Sci Res* 2015; 6(3): 544–551.

32. Mastor A, Khaing SL and Omar SZ. Users’ perspectives on Implanon in Malaysia, a multicultural Asian country. *Open Access J Contracept* 2011; 2: 79–84.
Yimer et al. 9

33. Burusie A. Reasons for premature removal of Implanon among users in Arsi zone, Oromia region, Ethiopia, 2013. Reprod Syst Sex Disord 2015; 4(1): 1–6.

34. Madden T, Eisenberg DL, Zhao Q, et al. Continuation of the etonogestrel implant in women undergoing immediate postabortion placement. Obstet Gynecol 2012; 120(5): 1053–1059.

35. Siyoum M, Mulaw Z, Abuhay M, et al. Implanon discontinuation rate and associated factors among women who ever used Implanon in the last three years in Debre Markos town, Northwest Ethiopia, 2016, cross-sectional study. ARC J Public Health Commn Med 2017; 2(1): 8–16.

36. Mutihir JT and Nyango DD. One-year experience with Implanon sub-dermal implants in Jos, Nigeria. Nigeria J Clin Pract 2010; 13(1): 28–31.

37. Ireland LD, Goyal V, Raker CA, et al. The effect of immediate postpartum compared to delayed postpartum and interval etonogestrel contraceptive implant insertion on removal rates for bleeding. Contraception 2014; 90(3): 253–258.

38. Hoggart L, Newton V and Dickson J. Full Report. Understanding long-acting reversible contraception: an in-depth investigation into sub-dermal contraceptive implant removal amongst young women in London. A report for the London Sexual Health Commissioning Programme, 2013, https://www.semanticscholar.org/paper/Full-Report.-Understanding-long-acting-reversible-A-Hoggart-Newton/12facf57c1bbe01ba5bec412c5dd76c7db209efa

39. Affandi B. An integrated analysis of vaginal bleeding patterns in clinical trials of Implanon®. Contraception 1998; 58(6): 99S–107S.

40. Croxatto HB, Urbancsek J, Massai R, et al. A multicentre efficacy and safety study of the single contraceptive implant Implanon®. Human Reproduction 1999; 14(4): 976–981.

41. Lakha F and Glasier AF. Continuation rates of Implanon® in the UK: data from an observational study in a clinical setting. Contraception 2006; 74(4): 287–289.

42. UNAIDS. Sustainable development goals. Transforming our world: 2015, 2030:338–350.

43. Federal Ministry of Health: Health sector transformation plan (HSTP)-2015/16–2019/20. Ethiopia Ministry of Health, 2015, https://www.globalfinancingfacility.org/sites/gff_new/files/Ethiopia-health-system-transformation-plan.pdf.

44. Gebrekidan KG, Nerea MK, Gerezgiher H, et al. Early Implanon discontinuation rate and its associated factors in health institutions of Mekelle City, Tigray, Ethiopia 2016/17. BMC Research Notes 2019; 12(1): 1–6.

45. Nageso A and Gebretsadik A. Discontinuation rate of Implanon and its associated factors among women who ever used Implanon in Dale District, Southern Ethiopia. BMC Women Health 2018; 18(1): 1–9.

46. Melkamu Asaye M, Syoum Nigussie T and Mequannt Ambaw W. Early Implanon discontinuation and associated factors among Implanon user women in Debre Tabor town, public health facilities, Northwest Ethiopia, 2016. Int J Reprod Med 2018; 2018: 3597487.

47. Gebre-Egziabher D, Medhanyie AA, Alemayehu M, et al. Prevalence and predictors of implanon utilization among women of reproductive age group in Tigray Region, Northern Ethiopia. Reproductive Health 2017; 14(1): 62.

48. Gebreyesus B, Berhe S and Bayray A. Assessment of long-acting and permanent contraceptive method utilization and associated factors among married women of reproductive age group in Adigrat town. Am J Adv Nurs Res 2015; 2(1): 36–45.

49. Tadesse A, Kondale M, Agedew E, et al. Determinant of Implanon discontinuation among women who ever used Implanon in Diguna Fango District, Wolayita zone, southern Ethiopia: a community based case control study. Int J Reprod Med 2017; 2017: 2861207.

50. Dagnew GW, Gelaw YM, Asresie MB, et al. Level and timing of Implanon discontinuation and associated factors among women who used Implanon in Andabet District, public health facilities, North-West Ethiopia. Biomed Res Int 2021; 2021: 6647660.

51. Sebatta G, Kaye DK and Mbalinda SN. Early contraceptive implants removal and its associated factors among women using implants at a National Referral Hospital, Kampala Uganda. BMC Women Health 2021; 21(1): 1–9.

52. Aziz MM, El-Gazzar AF and Elgibaly O. Factors associated with first-year discontinuation of Implanon in upper Egypt: clients’ and providers’ perspectives. BMJ Sex Reprod Health 2018; 44(4): 260–266.

53. Akilimali PZPKP. Incidence and determinants of Implanon discontinuation: Findings from a prospective cohort study in three health zones in Kinshasa, DRC. PLoS ONE 2020; 15(5): e0232582.

54. Duvan CI, Gözdemir E, Kaygusuz I, et al. Etonogestrel contraceptive implant (Implanon): analysis of patient compliance and adverse effects in the breastfeeding period. J Turkish German Gynecol Assoc 2010; 11(3): 141.

55. Mutihir JT and Nyango DD. Indications for removal of etonogestrel implants within two years of use in Jos, Nigeria. East Afr Med J 2010; 87(11): 461–464.

56. Dickerson LM, Diaz VA, Jordon J, et al. Satisfaction, early removal, and side effects associated with long-acting reversible contraception. Fam Med 2013; 45(10): 701–707.

57. Yehuala T, Melese E, Bogale KA, et al. Determinants of Implanon discontinuation among women who use Implanon at Bahir Dar town health institutions, Northwest Ethiopia, 2019: a case-control study. Evid Based Complement Alternat Med 2020; 2020: 9048609.

58. Dehendorf C, Levy K, Kelley A, et al. Women’s preferences for contraceptive counseling and decision making. Contraception 2013; 88(2): 250–256.